Literature DB >> 19083739

Kinship testing with X-chromosomal markers: mathematical and statistical issues.

Michael Krawczak1.   

Abstract

Use of X-chromosomal markers for kinship testing is meaningful if the identical-by-descent allele sharing probabilities of at least two individuals involved in the case differ under the different hypotheses made about the composite relationships. In this situation, optimal decision making about one or the other hypothesis should be based upon the likelihood ratio of the genotype data obtained. When more than one X-chromosomal marker is being used, this implies that the patterns of linkage and linkage disequilibrium between the respective loci have to be taken into account. Otherwise, the evidence extracted from the data by means of the likelihood ratio may be misleading. Exact likelihood calculations on complex pedigrees can be performed using available software such as, for example, the "LINKAGE" programmes widely used in genetic epidemiology. The required genetic maps can be created using physical location information available in public databases.

Mesh:

Substances:

Year:  2007        PMID: 19083739     DOI: 10.1016/j.fsigen.2007.01.014

Source DB:  PubMed          Journal:  Forensic Sci Int Genet        ISSN: 1872-4973            Impact factor:   4.882


  3 in total

1.  Development and population study of the 12 X-STR loci multiplexes PCR systems.

Authors:  Qiu-Ling Liu; Hu Zhao; Jian-Ding Chen; Xiao-Guang Wang; De-Jian Lu; Li Quan
Journal:  Int J Legal Med       Date:  2012-02-16       Impact factor: 2.686

2.  X chromosomal recombination--a family study analysing 39 STR markers in German three-generation pedigrees.

Authors:  Sandra Hering; Jeanett Edelmann; Christa Augustin; Eberhard Kuhlisch; Reinhard Szibor
Journal:  Int J Legal Med       Date:  2009-11-20       Impact factor: 2.686

3.  A general model for likelihood computations of genetic marker data accounting for linkage, linkage disequilibrium, and mutations.

Authors:  Daniel Kling; Andreas Tillmar; Thore Egeland; Petter Mostad
Journal:  Int J Legal Med       Date:  2014-11-26       Impact factor: 2.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.